Results 21 to 30 of about 20,409 (197)

[Pegylation and interferons in multiple sclerosis]

Farmeconomia. Health economics and therapeutic pathways, 2016
Pegylation is a procedure used for drug development since the 1970s and consists of the conjugation of a polyethylene glycol molecule (PEG) to a drug. PEG has shown to be safe and effective in improving the pharmacokinetic and pharmacodynamic profile of drugs.
Cecilia Saleri, Diego Centonze, Giulia Vestri, Elisa Puma, Sergio Iannazzo, Luigi Giuliani, L Santoni, Pier Luigi Canonico   +7 more
openaire   +4 more sources

Pegylated Interferon (Alone or With Ribavirin) for Chronic Hepatitis C in Haemodialysis Population

Kidney & Blood Pressure Research, 2015
Background/Aims: Hepatitis C virus infection remains prevalent among patients undergoing long-term haemodialysis and has a detrimental impact on survival in this population.
Mario Espinosa, Jesùs Hernàndez, Maria Dolores Arenas, Fernando Carnicer, Carlos Caramelo, Fabrizio Fabrizi   +5 more
doaj   +1 more source

Interferons lambda – therapeutic application

Сибирский научный медицинский журнал, 2020
Interferons are a group of protein molecules with a broad spectrum of effects on the human body. Interferon lambda (type III interferon) was discovered comparatively recently about 20 years ago and its action is still poorly understood.
N. A. Kikhtenko, L. A. Oleynik, V. K. Makarov, E. P. Nagorskaya, P. G. Madonov   +4 more
doaj   +1 more source

Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review

Revista do Instituto de Medicina Tropical de São Paulo, 2019
Chronic Hepatitis C relapse after liver transplantation can lead to graft failure within a short time period. The high efficacy and good safety profile of direct-acting antivirals has led to consensual recommendations for using interferon-free treatment ...
Marcos Mucenic, Ajacio Bandeira de Melo Brandão, Claudio Augusto Marroni, Alfeu de Medeiros Fleck Junior, Maria Lucia Zanotelli, Ian Leipnitz, Mário Henrique Meine, Guillermo Kiss, Juliano Martini, Eduardo Soares Schlindwein, Ane Micheli Costabeber, Fernanda Karlinsky Rodrigues Sacco, Giovana Rossato, Guido Pio Cracco Cantisani   +13 more
doaj   +1 more source

Evaluation of the long-term outcomes of patients with hepatitis delta

Journal of Infection in Developing Countries
Objective: To evaluate the long-term outcomes of hepatitis delta patients, including cirrhosis and hepatocellular carcinoma (HCC), based on clinical and laboratory data.
Muhammet Salih Tarhan, Habip Gedik, Kadriye Kart-Yasar   +2 more
doaj   +1 more source

Navigating adverse immunostimulation: A practical guide for clinical researchers

British Journal of Clinical Pharmacology, EarlyView.
Problem Setting As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS). Solution At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while
Juliette A. van den Noort, Anouk C. Meijs, Naomi B. Klarenbeek, Matthijs Moerland   +3 more
wiley   +1 more source

Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment

AIDS Research and Therapy, 2017
Background Clinicians are incorporating patient-reported outcomes in the management of HIV-infected persons co-infected with hepatitis C virus (HCV), but there are no validated inventories to monitor symptoms of patients during HCV therapy.
Edward R. Cachay, Craig Ballard, Bradford Colwell, Francesca Torriani, Charles Hicks, Wm. Christopher Mathews   +5 more
doaj   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Response to pegylated interferon in a COVID‐19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus

Clinical Case Reports, 2021
A 61‐year‐old male on everolimus had chronic SARS‐CoV‐2 infection. Addition of pegylated interferon cleared viral RNA and supports combination therapy with everolimus plus interferon for COVID‐19.
Arthur E. Frankel, Wai C. Yip, Eknath Naik, Hans C. Hasselbalch   +3 more
doaj   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source